Overview
An in-depth look at big pharma's flagship company The Merck Druggernaut takes readers inside Merck, the world's second most profitable drug company and maker of the world's bestselling drug, Prilosec. Consistently named one of Fortune magazine's Most Admired Companies, Merck struggles to maintain its reputation for being the most ethical of the big drug makers, refusing to slash research and development budgets in the face of declining profits, falling stock market prices, and questionable accounting. Author Fran Hawthorne, one of the leading journalists covering healthcare, has written an excellent examination of a business paragon with much-needed insight on the cutthroat world of pharmaceuticals. It's a story that will interest the business world as well as consumer and healthcare advocates by detailing the vital issues in medicine and healthcare today. More than just a compelling story of success in a difficult industry, more than simply the biography of one of big business's most recognizable names, The Merck Druggernaut takes a thoughtful look at some of the major issues of our time and the way those issues intertwine with the world of business. Fran Hawthorne (New York, NY) is the Assistant Managing Editor at Crain's New York Business. She has been covering business for more than twenty years for such publications as Fortune, BusinessWeek, and Institutional Investor, with a prevailing interest in healthcare and pharmaceuticals. At Crain's, she spearheads the publication of two to three special healthcare issues per year.
Full Product Details
Author: Fran Hawthorne
Publisher: John Wiley & Sons Inc
Imprint: John Wiley & Sons Inc
Dimensions:
Width: 14.20cm
, Height: 2.20cm
, Length: 21.80cm
Weight: 0.352kg
ISBN: 9780471679066
ISBN 10: 0471679062
Pages: 290
Publication Date: 11 March 2005
Audience:
General/trade
,
Professional and scholarly
,
College/higher education
,
General
,
Professional & Vocational
Format: Paperback
Publisher's Status: Active
Availability: Out of stock
The supplier is temporarily out of stock of this item. It will be ordered for you on backorder and shipped when it becomes available.
Reviews
""Unlike some other critics, however, she understands and communicates the incredible complexity of discovering new drugs and introducing them to the market."" (New York Times, March 23, 2003)
Author Information
FRAN HAWTHORNE, a senior contributing editor of Institutional Investor, has connections deep within the business and finance communities. Hawthorne has been covering business and healthcare for more than twenty years for such publications as Fortune, BusinessWeek, and Crain's New York Business. She is the author of Inside the FDA, which is also published by Wiley.
